Image: Profile picture of Alessandro Cataliotti

Alessandro Cataliotti

Group Leader & Professor

Cataliotti group

MD, PhD, Specialist in Internal Medicine

UiO and OUH employee

Awards, committees and memberships
Recipient, as principal investigator, of several national and international awards and scientific recognitions including NIH R01 grants, a Doris Duke Charitable Foundation Scientific Development grant, Helse Sør Øst grants, Nasjonaforeiningen for Folkehelsen grants, the American Society of Hypertension Young Scholar Award, and several others from both public institutions and private foundations.

Academic interests
My general research interests include cardiac endocrinology and physiology in human and experimental models of cardiovascular and renal diseases, such as congestive heart failure, hypertension, atherosclerosis, and renal failure. I have a particular interest in the natriuretic peptides and their regulatory actions on cardiovascular and renal homeostasis in hypertension, heart failure and renal dysfunction. This interest has led to the development of natriuretic peptide based chronic therapy (oral, subcutaneous, and gene delivery). I have been the principal investigator (PI) of an NIH funded grant on innovative gene delivery strategies for the treatment of organ damage secondary to hypertension, e.g. hypertensive heart disease and renal fibrosis and dysfunction. I led studies focusing on the effects of natriuretic peptides treatment in preclinical models of diastolic dysfunction and humans with hypertension resistant to standard treatment. My interest is also on cardiorenal epidemiology and biomarkers development and discovery of novel drugs for the treatment of cardiovascular and renal diseases. My research resulted in the publications of more that hundred manuscripts and in five patents.

Research area

  • Cardiorenal syndrome
  • Diastolic dysfunction
  • Heart failure
  • Hypertension
  • Ischemic heart disease

Latest publications

view all >
da Silva GJJ, Altara R, Booz GW, Cataliotti A (2021)
Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases
Front Physiol, 12, 691407
PubMed 34305645 DOI 10.3389/fphys.2021.691407
Kaplan A, Altara R, Manca M, Gunes HM, Cataliotti A, Booz GW, Zouein FA (2021)
Distorted assessment of left atrial size by echocardiography in patients with increased aortic root diameter
Egypt Heart J, 73 (1), 55
PubMed 34173898 DOI 10.1186/s43044-021-00177-2
Frisk M, Le C, Shen X, Røe ÅT, Hou Y, Manfra O, Silva GJJ, van Hout I, Norden ES, Aronsen JM, Laasmaa M, Espe EKS, Zouein FA, Lambert RR, Dahl CP, Sjaastad I, Lunde IG, Coffey S, Cataliotti A, Gullestad L, Tønnessen T, Jones PP, Altara R, Louch WE (2021)
Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction
J Am Coll Cardiol, 77 (4), 405-419
PubMed 33509397 DOI 10.1016/j.jacc.2020.11.044
Nordén ES, Bendiksen BA, Andresen H, Bergo KK, Espe EK, Hasic A, Hauge-Iversen IM, Veras I, Hussain RI, Sjaastad I, Christensen G, Cataliotti A (2021)
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
ESC Heart Fail, 8 (2), 918-927
PubMed 33497525 DOI 10.1002/ehf2.13177
Bergo KK, Larstorp AC, Hoffmann P, Hjørnholm U, Cataliotti A, Høieggen A, Rostrup M, Fadl Elmula FEM (2020)
Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension
Blood Press, 30 (1), 31-40
PubMed 32633141 DOI 10.1080/08037051.2020.1789446
view all >